Tocilizumab in critically ill COVID-19 patients: An observational study

Tocilizumab decreases inflammatory response in the cytokine storm which is one of the mechanisms behind the development of ARDS in COVID-19 patients. The objective of our study was to determine response of tocilizumab in patients suffering from COVID-19 by analyzing clinical parameters and inflammat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mushtaq, Muhammad Z., Mahmood, Saad B.Z., Almas, Aysha, Ather Wasti, Syed, Ahsan Ali, Syed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604692/
https://www.ncbi.nlm.nih.gov/pubmed/34838490
http://dx.doi.org/10.1016/j.intimp.2021.108384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604692/
https://www.ncbi.nlm.nih.gov/pubmed/34838490
http://dx.doi.org/10.1016/j.intimp.2021.108384

Ejemplares similares